Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research note issued on Friday. They presently have a $10.00 price target on the stock. Mizuho’s price objective indicates a potential upside of 101.21% from the company’s previous close.
Other equities research analysts have also issued research reports about the stock. Cowen set a $11.00 price target on shares of Viveve Medical and gave the company a “buy” rating in a report on Monday, October 23rd. Northland Securities assumed coverage on shares of Viveve Medical in a research report on Friday. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, ValuEngine downgraded shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.00.
Viveve Medical (NASDAQ:VIVE) traded down $0.22 during trading hours on Friday, hitting $4.97. 250,000 shares of the stock were exchanged, compared to its average volume of 138,267. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. Viveve Medical has a 1 year low of $3.75 and a 1 year high of $11.16. The stock has a market capitalization of $96.55, a PE ratio of -2.31 and a beta of -0.67.
Large investors have recently bought and sold shares of the business. Rhumbline Advisers acquired a new position in Viveve Medical during the second quarter worth $110,000. JPMorgan Chase & Co. acquired a new position in Viveve Medical during the second quarter worth $151,000. Virtu KCG Holdings LLC acquired a new position in Viveve Medical during the second quarter worth $169,000. Schwab Charles Investment Management Inc. acquired a new position in Viveve Medical during the second quarter worth $189,000. Finally, California State Teachers Retirement System acquired a new position in Viveve Medical during the second quarter worth $190,000. Institutional investors own 66.90% of the company’s stock.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.